From: Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea
2005 | 2006 | 2007 | 2008 | 2009 | Average | |
---|---|---|---|---|---|---|
Year-on-year increased statin expenditure rate (%)* (T) | 35.92 | 26.90 | 11.60 | 14.99 | 21.97 | |
Core medicines (year-to-year rates of increase: %, A) | 46.62 | 23.61 | 2.32 | 14.17 | 18.24 | |
  - Price (△P) | −7.18 | −0.33 | −0.22 | −6.21 | −2.98 | |
  -Within-component mix (generic mix) | 5.36 | −2.12 | −1.77 | −2.06 | −0.90 | |
  -Between-component mix | 4.54 | 0.83 | 0.10 | 1.19 | 1.36 | |
      (Ingredient mix) | ||||||
  - Volume (△Q) | 47.94 | 32.21 | 5.04 | 21.58 | 23.48 | |
New entrants (year-to-year rates of increase: %, B) | 2.69 | 3.30 | 10.54 | 0.96 | 6.43 | |
  - New molecular entities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
  - New medicines | 0.00 | 0.00 | 0.01 | 0.34 | 0.12 | |
  - New generic medicines | 1.87 | 3.23 | 10.53 | 0.30 | 5.13 | |
  - Others | 0.82 | 0.07 | 0.00 | 0.32 | 0.26 | |
Exiting medicines (year-to-year rates of increase: %, C) | −13.39 | 0.00 | −1.26 | −0.14 | −2.70 |